HMPL-813 in Treating Patients With Glioblastoma

Inclusion Criteria: 1. Histologically confirmed glioblastoma 2. Standard treatment failed or no standard treatment 3. EGFR gene amplification 4. Clearly measurable lesions (according to Response Assessment in Neuro-Oncolog (RANO)) 5. Age ≥ 18 6. Eastern Cooperative Oncology Group (ECOG) score ≤2 Exclusion Criteria: 1. Use of Antiepileptic drugs were used\] within 2 weeks before enrollment 2. Immunotherapy, anti-angiogenesis or EGFR TKI and its downstream pathway signaling molecules and other targeted drugs within 4 weeks before enrollment; temozolomide chemotherapy, cranial radiotherapy or other systemic anti-tumor therapy within 3 weeks before enrollment 3. Previous toxic effects of anticancer therapy have not yet been recovered (defined as not restored to 0 or 1 level, except alopecia) or have not been fully recovered from previous surgery 4. Uncontrolled active infections such as acute pneumonia, Hepatitis B Virus (HBV) and so on 5. Eye disease or dry eye syndrome history 6. Positive pregnancy tested result